Literature DB >> 21837437

The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years.

Judith Haschka1, Friederike Kühne, Christian Muschitz, Thomas Pirker, Roland Kocijan, Christina Bittighofer, Angela Trubrich, Heinrich Resch.   

Abstract

Atypical fractures under long term treatment with bisphosphonates (BP) have been reported, although no causal connection has been known. As an explanation the suppression of bone turnover with poor bone metabolism and consequently deterioration of bone microarchitecture has been suggested. In our case we describe retrospectively the course of radiological and clinical changes in a 75 years old female patient who has been treated with oral BP due to postmenopausal osteoporosis over 15 years. After 10 years of treatment she developed a cortical stress fracture in the subtrochanteric region of the femoral shaft, which finally caused a spontaneous atypical subtrochanteric fracture 5 years later.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837437     DOI: 10.1007/s00508-011-0034-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  8 in total

1.  Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Authors:  Dennis M Black; Michael P Kelly; Harry K Genant; Lisa Palermo; Richard Eastell; Christina Bucci-Rechtweg; Jane Cauley; Ping Chung Leung; Steven Boonen; Arthur Santora; Anne de Papp; Douglas C Bauer
Journal:  N Engl J Med       Date:  2010-03-24       Impact factor: 91.245

2.  Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).

Authors:  Yaser M Alkhiary; Louis C Gerstenfeld; Elizabeth Krall; Michael Westmore; Masahiko Sato; Bruce H Mitlak; Thomas A Einhorn
Journal:  J Bone Joint Surg Am       Date:  2005-04       Impact factor: 5.284

3.  Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2010-09-15       Impact factor: 5.958

4.  Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

5.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

6.  Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.

Authors:  Per Aspenberg; Harry K Genant; Torsten Johansson; Antonio J Nino; Kyoungah See; Kelly Krohn; Pedro A García-Hernández; Christopher P Recknor; Thomas A Einhorn; Gail P Dalsky; Bruce H Mitlak; Anke Fierlinger; Mark C Lakshmanan
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

8.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.